Abstract

To describe breast cancer treatment patterns among premenopausal women by age and time since last pregnancy. Data were analyzed from 1179 women diagnosed with premenopausal breast cancer in the Carolina Breast Cancer Study. Of these, 160 had a recent pregnancy (within 5years of cancer diagnosis). Relative frequency differences (RFDs) and 95% confidence intervals (CIs) were used to compare cancer stage, treatment modality received, treatment initiation delay (> 30days), and prolonged treatment duration (> 2 to > 8months depending on the treatment received) by age and recency of pregnancy. Recently postpartum women were significantly more likely to have stage III disease [RFD (95% CI) 12.2% (3.6%, 20.8%)] and to receive more aggressive treatment compared to nulliparous women. After adjustment for age, race and standard clinical tumor characteristics, recently postpartum women were significantly less likely to have delayed treatment initiation [RFD (95% CI) -11.2% (-21.4%, -1.0%)] and prolonged treatment duration [RFD (95% CI) -17.5% (-28.0%, -7.1%)] and were more likely to have mastectomy [RFD (95% CI) 14.9% (4.8%, 25.0%)] compared to nulliparous. Similarly, younger women (< 40years of age) were significantly less likely to experience prolonged treatment duration [RFD (95% CI) -5.6% (-11.1%, -0.0%)] and more likely to undergo mastectomy [RFD (95% CI) 10.6% (5.2%, 16.0%)] compared to the study population as a whole. These results suggest that recently postpartum and younger women often received prompt and aggressive breast cancer treatment. Higher mortality and recurrence among recently pregnant women are unlikely to be related to undertreatment.

Highlights

  • MethodsData were analyzed from 1,179 women diagnosed with premenopausal breast cancer in the Carolina Breast Cancer Study

  • Ethics approval: All study protocols were approved by the Office of Human Research Ethics, Institutional Review Board at the University of North Carolina at Chapel Hill (UNC)

  • Treatment modalities and prolonged treatment duration Time to treatment initiation was defined as the time between breast cancer diagnosis and first treatment; this information was abstracted from medical records

Read more

Summary

Methods

The CBCS phase III is a population-based study of women diagnosed with breast cancer in 44 counties of central and eastern North Carolina (2008-2013, N=2998); study details have been described previously [45,46,47,48]. Treatment modalities and prolonged treatment duration Time to treatment initiation (in days) was defined as the time between breast cancer diagnosis and first treatment (defined as surgery, adjuvant or neoadjuvant chemotherapy, or radiation); this information was abstracted from medical records. Information on treatment type, including type of surgery (mastectomy vs breast-conserving surgery), chemotherapy receipt (yes vs no), radiation therapy receipt (yes vs no), and hormone therapy (yes vs no), was abstracted from medical records. Due to the limited cell size for recently (0-5 years) postpartum women without chemotherapy (n=20) and hormone therapy (n=14) treatment groups, these models were only adjusted for age and race. P-values were two-sided with an alpha of 0.05 for statistical significance

Results
Conclusion
Discussion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.